SBIR/STTR Research Award

D-3 Phosphorylated Phosphoinositides and Analogs

Award identifier b3865f8671991d2e55c595d19d360ce842f0778e9245ca936e3d24e5494366d8Awarding agency Department of Health and Human Services

Award amount

$741,581

Program and phase

SBIR · Phase II

Award year

1995

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
Not reported
Recipient company
NUTRIMED BIOTECH
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

The recently discovered enzyme phosphatidylinositol 3-kinase (PI 3- kinase) physically associates with and is phosphorylated by activated growth factor receptors and oncogenes which manifest protein-tyrosine kinase activity. It phosphorylates phosphatidylinositols specifically at the D-3-hydroxyl to produce the 3-phosphorylated phosphoinositides, 3-PPI, comprising phosphatidylinositol 3-phosphate, PI(3)P, phosphatidylinositol 3,4-bisphosphate, PI(3,4)P2, and phosphatidylinositol 3,4,5-trisphosphate, PI(3,4,5)P3. Mutational studies of growth factor receptors and oncogenes have shown that the associated PI 3-kinase and its products PI(3,4)P2 and PI(3,4,5)P3 regulate cell growth and transformation. The 3-PPI are not physiological substrates for the PI-specific phospholipases C, and so the intact lipids have been suggested as novel critical second messengers of growth signals. Biochemical studies to determine the cellular targets of PI(3,4)P2 and PI(3,4,5)P3, the metabolic fate of these lipids, and their roles in the cell cycle have been handicapped because well characterized 3-PPI samples are not readily available; there is no commercial source. These materials are needed as research probes for defining their biochemical and physiological roles. The materials may also be useful for developing new anticancer agents and applications in medical biotechnology. Practical synthetic methods for 3-PPI are not available. The overall objectives are to develop synthetic methods and analogues for the 3-PPI and to prepare and characterize these by physicochemical and spectro- metric techniques. A strategy based on total synthesis and partial synthesis as complementary approaches is suggested. During Phase I, the feasibility of these complementary approaches will be tested for the synthesis of PI(3,4,5)P3, and the product will be fully characterized by analytical, physicochemical and spectrometric measurements. In Phase II, these approaches will be adapted and extended for the syntheses of PI(3)P, PI3,4)P2, isomers and analogues.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.